Publicaciones - IR Sant Pau

Buscar

01/02/2026 Summary of the European Association of Urology/European Society of paediatric urology guidelines on transition in urology

Skott, M, Gnech, M, Bujons, A, Hoen, L, Burgu, B, Rawashdeh, YF, Bogaert, G, Quaedackers, J, Pakkasjärvi, N, Van Uitert, A, Kennedy, U, Yuan, YH, Radmayr, C, Castagnetti, M, O'Kelly, F. Summary of the European Association of Urology/European Society of paediatric urology guidelines on transition in urology. Journal of Pediatric Urology. 2026; 22(1)DOI:10.1016/j.jpurol.2025.10.002. PMID:41203536. IF:1.900(Q2/5D).

01/03/2026 Comparative performance of virtual basket plus Magneto pulse modulations versus standard pulse holmium laser lithotripsy for urinary stones: A multicenter study

Socarrás, MER, Perri, D, Azabache, AK, Valle, J, Rico, L. Comparative performance of virtual basket plus Magneto pulse modulations versus standard pulse holmium laser lithotripsy for urinary stones: A multicenter study. EUROPEAN UROLOGY. 2026; 89DOI:. PMID:. IF:25.200(Q1/1D).

01/02/2026 Ambient temperature and child nutritional status of more than 6 million children in Brazil: a cohort study

Ribeiro-Silva, RD, Luz, LP, Sacramento, LS, Cortes, TR, Ribeiro, LHL, Pepper, M, Delgado, D, Pescarini, JM, Rebouças, P, Silveira, IH, Costa, PRD, Ranzani, OT, Paixao, ES, Barreto, ML. Ambient temperature and child nutritional status of more than 6 million children in Brazil: a cohort study. Lancet Planetary Health. 2026; 10(2)DOI:10.1016/j.lanplh.2026.101428. PMID:41791402. IF:21.600(Q1/1D).

01/04/2026 High ambient temperature effects on the anthropometric status of the population: A systematic review and meta-analysis

Costa, PRD, Ribeiro-Silva, RD, Santos, RD, Magalhaes, KBBD, Cerqueira, ES, Rocha, AD, Luz, LP, Ribeiro, LHL, Ranzani, OT, Silveira, I, Pepper, M, Paixao, ES, Barreto, ML. High ambient temperature effects on the anthropometric status of the population: A systematic review and meta-analysis. PLoS One. 2026; 21(4)DOI:10.1371/journal.pone.0344186. PMID:41920813. IF:2.600(Q2/4D).

06/02/2026 Immune-mediated protection and enhancement of dengue drives patterns of infant cases in Brazil

Hitchings, MDT, Huang, AT, Ranzani, OT, García-Carreras, B, Nogueira, ML, Ko, AI, Croda, J, Salje, H, Cummings, DAT. Immune-mediated protection and enhancement of dengue drives patterns of infant cases in Brazil. Nature Communications. 2026; 17(1)DOI:10.1038/s41467-026-69111-x. PMID:41651817. IF:15.700(Q1/1D).

21/04/2026 Clarifying the SOFA-2 Score-Reply

Ranzani, OT, Singer, M, Moreno, RP. Clarifying the SOFA-2 Score-Reply. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2026; 335(15)DOI:10.1001/jama.2026.0313. PMID:41837958. IF:55.000(Q1/1D).

12/08/2024 Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants

Furlano, M, Pilco-Teran, M, Pybus, M, Martínez, V, Aza-Carmona, M, Peris, AR, Pérez-Gomez, V, Berná, G, Mazon, J, Hernández, J, de Arizón, LF, Viera, E, Gich, I, Pérez, HV, Gomá-Garcés, E, Dolon, JLA, Ars, E, Torra, R. Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2024; 39(9)DOI:10.1093/ndt/gfae031. PMID:38317457. IF:5.600(Q1/1D).

01/01/2024 Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period

Benjumea, C, Navarro, F, Tarrés, CA. Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period. JOURNAL OF MEDICAL MICROBIOLOGY. 2024; 73(6)DOI:10.1099/jmm.0.001846. PMID:38935081. IF:2.000(Q3/8D).

01/03/2025 Breast radiotherapy planning: A decision-making framework using deep learning

Gallego, P, Ambroa, E, Pérezalija, J, Jornet, N, Anson, C, Tejedor, N, Vivancos, H, Ruiz, A, Barceló, M, Dominguez, A., Riu, V, Roda, J, Carrasco, P, Balocco, S, Díaz, O. Breast radiotherapy planning: A decision-making framework using deep learning. MEDICAL PHYSICS. 2025; 52(3)DOI:10.1002/mp.17527. PMID:39625151. IF:3.200(Q1/3D).

01/01/2026 Opinion and Knowledge of Pulmonologists, Primary Care Physicians, and Nurses About Inhaled Therapy in COPD. Inhal-Epoc Survey

De Miguel-Díez, J, Donaire, JG, Sáenz, JTG, Carrero, JAT, Feliu, RA, Culebra, NC, Plaza, V. Opinion and Knowledge of Pulmonologists, Primary Care Physicians, and Nurses About Inhaled Therapy in COPD. Inhal-Epoc Survey. International Journal of Chronic Obstructive Pulmonary Disease. 2026; 21DOI:10.2147/COPD.S499279. PMID:41710326. IF:3.100(Q2/4D).

09/04/2026 Neurogenic cough in CANVAS syndrome: objective cough monitoring reveals a distinctive clinical pattern

Crespo-Lessmann, A, Bustamante, D, Vélez-Segovia, E, Najas, V, Palones, E. Neurogenic cough in CANVAS syndrome: objective cough monitoring reveals a distinctive clinical pattern. JOURNAL OF NEUROLOGY. 2026; 273(5)DOI:10.1007/s00415-026-13784-3. PMID:41954751. IF:4.600(Q1/2D).

01/01/2025 Influence of Outdoor Air Pollutants on Asthma: A Narrative Review.

Espejo, David, Plaza, Vicente, Quirce, Santiago, Trigueros, Juan Antonio, Munoz, Xavier. Influence of Outdoor Air Pollutants on Asthma: A Narrative Review.. Open Respiratory Archives. 2025; 7(3)DOI:10.1016/j.opresp.2025.100448. PMID:. IF:(Q/D).

30/01/2025 Fenotipo hipersecretor en asma, diagnóstico e implicaciones

Crespo-Lessman, A, Vélez-Segovia, E, Sáez-Elizagaray, Javier. Fenotipo hipersecretor en asma, diagnóstico e implicaciones. Revista de Asma. 2025; 10(1)DOI:10.69703/asma.v10i1.2. PMID:. IF:(Q/D).

01/10/2022 Quality of interpersonal relations among emergency medical staff in Catalonia and differences in hospital and prehospital settings: a survey study

Jacob, J, Gene, E, Escalada, X, Villamor, A, Hernandez, R, Miro, O, Puig-Campmany M., ALONSO, GILBERTO. Quality of interpersonal relations among emergency medical staff in Catalonia and differences in hospital and prehospital settings: a survey study. EMERGENCIAS. 2022; 34(5)DOI:. PMID:36217936. IF:5.500(Q1/2D).

01/02/2025 Role of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas

Majercakova, K, Aguilar, NT, Verdum, JI, Bargallo, HV, Capel, AV, Soto, MM, Melcon, GGD, Cordero, JVR, Gonzalez-Lopez, JA, Rosell, SB, Jover, DH, Mitre, SR, Ibanez, AP, Sebio, A, Sancho-Pardo, G. Role of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas. Cancers. 2025; 17(4)DOI:10.3390/cancers17040624. PMID:40002219. IF:4.400(Q2/3D).

01/03/2024 Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group

Muñoz NG, Ortega S, Solanich X, Cid J, Díaz M, Moreno AB, Ancochea Á, Santos M, Hernández I, Sanchez JM, Luaña A, García J, Escoda L, Medina L, Ferrer GJ, López J, Céspedes R, Díaz JA, Pons V, Valcárcel D, Grifols JR. Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group. Blood Transfusion. 2024; 22(2)DOI:10.2450/BloodTransfus.522. PMID:37677097. IF:2.300(Q2/5D).

27/08/2024 Antibodies in Autoimmune Neuropathies

Pascual-Goñi, E, Caballero-avila, M, Querol, L. Antibodies in Autoimmune Neuropathies. NEUROLOGY. 2024; 103(4)DOI:10.1212/WNL.0000000000209725. PMID:39088795. IF:8.500(Q1/1D).

01/03/2024 Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?

Baeza, I, de la Serna, E, Mezquida, G, Cuesta, MJ, Vieta, E, Amoretti, S, Lobo, A, González-Pinto, A, Díaz-Caneja, CM, Corripio, I, Valli, I, Puig, O, Mané, A, Bioque, M, Ayora, M, Bernardo, M, Castro-Fornieles, J. Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 2024; 33(3)DOI:10.1007/s00787-023-02196-7. PMID:37027026. IF:4.900(Q1/1D).

03/09/2024 Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers

Fuentes-Claramonte, P, Estradé, A, Solanes, A, Ramella-Cravaro, V, Garcia-Leon, MA, de Diego-Adeliño, J, Molins, C, Fung, E, Valenti, M, Anmella, G, Pomarol-Clotet, E, Oliver, D, Vieta, E, Radua, J, Fusar-Poli, P. Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers. Schizophrenia Bulletin Open. 2024; 5(1)DOI:10.1093/schizbullopen/sgae018. PMID:39228676. IF:(Q/D).

01/10/2022 Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Delaby, C, Teunissen, CE, Blennow, K, Alcolea, D, Arisi, I, Amar, EB, Beaume, A, Bedel, A, Bellomo, G, Bigot-Corbel, E, Bjerke, M, Blanc-Quintin, MC, Boada, M, Bousiges, O, Chapman, MD, DeMarco, ML, D'Onofrio, M, Dumurgier, J, Dufour-Rainfray, D, Engelborghs, S, Esselmann, H, Fogli, A, Gabelle, A, Galloni, E, Gondolf, C, Grandhomme, F, Grau-Rivera, O, Hart, M, Ikeuchi, T, Jeromin, A, Kasuga, K, Keshavan, A, Khalil, M, Kortvelyessy, P, Kulczynska-Przybik, A, Laplanche, JL, Lewczuk, P, Li, QX, Lleo, A, Malaplate, C, Marquie, M, Masters, CL, Mroczko, B, Nogueira, L, Orellana, A, Otto, M, Oudart, JB, Paquet, C, Paoletti, FP, Parnetti, L, Perret-Liaudet, A, Peoc'h, K, Poesen, K, Puig-Pijoan, A, Quadrio, I, Quillard-Muraine, M, Rucheton, B, Schraen, S, Schott, JM, Shaw, LM, Suarez-Calvet, M, Tsolaki, M, Tumani, H, Udeh-Momoh, CT, Vaudran, L, Verbeek, MM, Verde, F, Vermunt, L, Vogelgsang, J, Wiltfang, J, Zetterberg, H, Lehmann, S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. ALZHEIMERS & DEMENTIA. 2022; 18(10)DOI:10.1002/alz.12545. PMID:34936194. IF:14.000(Q1/1D).

01/09/2021 Replication study of plasma proteins relating to Alzheimer's pathology

Shi, L, Winchester, LM, Westwood, S, Baird, AL, Anand, SN, Buckley, NJ, Hye, A, Ashton, NJ, Bos, I, Vos, SJB, ten Kate, M, Scheltens, P, Teunissen, CE, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, R, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lleo, A, Sala, I, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Freund-Levi, Y, Frolich, L, Dobricic, V, Legido-Quigley, C, Barkhof, F, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Lill, CM, Bertram, L, Visser, PJ, Kolb, HC, Narayan, VA, Lovestone, S, Nevado-Holgado, AJ. Replication study of plasma proteins relating to Alzheimer's pathology. ALZHEIMERS & DEMENTIA. 2021; 17(9)DOI:10.1002/alz.12322. PMID:33792144. IF:16.655(Q1/1D).

10/07/2024 Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study

Ulugut, H, Bertoux, M, Younes, K, Montembeault, M, Fumagalli, GG, Samanci, B, Illan-Gala, I, Kuchcinski, G, Leroy, M, Thompson, JC, Kobylecki, C, Santillo, AF, Englund, E, Waldö, ML, Riedl, L, van den Stock, J, Vandenbulcke, M, Vandenberghe, R, Laforce, R Jr, Ducharme, S, Pressman, PS, Caramelli, P, de Souza, LC, Takada, LT, Gurvit, H, Hansson, O, Diehl-Schmid, J, Galimberti, D, Pasquier, F, Miller, BL, Scheltens, P, Ossenkoppele, R, van der Flier, WM, Barkhof, F, Fox, NC, Sturm, VE, Miyagawa, T, Whitwell, JL, Boeve, B, Rohrer, JD, Gorno-Tempini, ML, Josephs, KA, Snowden, J, Warren, JD, Rankin, KP, Pijnenburg, YAL. Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study. ALZHEIMERS & DEMENTIA. 2024; 20(8)DOI:10.1002/alz.14076. PMID:38982845. IF:11.100(Q1/1D).

03/06/2023 zZ Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities-focused research

Franzen, S, Nuytemans, K, Bourdage, R, Caramelli, P, Ellajosyula, R, Finger, E, Illan-Gala, I, Loi, SM, Morhardt, D, Pijnenburg, Y, Rascovsky, K, Williams, MM, Yokoyama, JS, Alladi, S, Ayhan, Y, Broce, I, Castro-Suarez, S, Coleman, K, de Souza, LC, Dacks, PA, de Boer, SCM, de Leon, J, Dodge, S, Grasso, S, Gupta, V, Gupta, V, Ghoshal, N, Kamath, V, Kumfor, F, Matias-Guiu, JA, Narme, P, Nielsen, TR, Okhuevbie, D, Pina-Escudero, SD, Garcia, RR, Scarioni, M, Slachevsky, A, Suarez-Gonzalez, A, Tee, BL, Tsoy, E, Ulugut, H, Babulal, GM, Onyike, CU. zZ Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities-focused research. ALZHEIMERS & DEMENTIA. 2023; 19(12)DOI:10.1002/alz.13129. PMID:37270665. IF:13.100(Q1/1D).

01/09/2024 Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria

Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(9)DOI:10.3390/antibiotics13090874. PMID:39335047. IF:4.600(Q1/2D).

08/08/2024 Evolving trends in neuropsychological profiles of post COVID-19 condition: A 1-year follow-up in individuals with cognitive complaints

Grunden, N, Calabria, M, García-Sánchez, C, Pons, C, Arroyo, JA, Gómez-Ansón, B, Estévez-Garcia, MD, Belvís, R, Morollón, N, Cordero-Carcedo, M, Mur, I, Pomar, V, Domingo, P. Evolving trends in neuropsychological profiles of post COVID-19 condition: A 1-year follow-up in individuals with cognitive complaints. PLoS One. 2024; 19(8)DOI:10.1371/journal.pone.0302415. PMID:39116061. IF:2.600(Q2/4D).

01/04/2024 Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Lora-Tamayo, J, Mancheño-Losa, M, Meléndez-Carmona, MA, Hernández-Jiménez, P, Benito, N, Murillo, O. Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review. Antibiotics-Basel. 2024; 13(4)DOI:10.3390/antibiotics13040293. PMID:38666969. IF:4.600(Q1/2D).

01/03/2026 Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review

Calvo-Río, V, Secada-Gómez, C, Gutiérrez, AM, Retuerto-Guerrero, M, Font, J, Casafont-Solé, I, Mayo-Juanatey, A, Sancho, JJA, Freites, D, Hormigos, C, Puñal, NG, Arribas, GG, Sanchez, JRM, García-Valle, A, Ibañez, M, Morillo, FL, Manzanares, AG, Sandoval-Moreno, S, Cortes-Hernandez, J, Sanchez, DP, Lojo, L, Pérez, ECC, Collado, P, Larios, CA, Icardo, LS, Labrador-Sánchez, E, Peralta-Ginés, C, Onaindia, IU, Plaza-Aulestia, N, Malone, MM, de Salazar, JRG, Corteguera, M, Cebrián-Méndez, L, Pages, FAA, Riazuelo, JRL, Canales, MDF, Hernández, MJA, Bufort, MG, Pàmies, A, de Ardanaz, LS, Aguirre-del-Pino, R, Lefler, JAC, Seijas-Lopez, A, Cubero, MDC, Cofiño, ALC, Ortiz-Santamaria, V, Piñeiro, ML, Calvo, CO, Lopez, CA, Urruticoechea-Arana, A, Magallon, BG, Alfaro, AVA, Rodriguez, SL, Olivares, MS, Villar, PL, Brandy-García, AM, Vilamajo, IR, Martos, AG, Lopez, BPM, Urmeneta, GS, Martín, CC, Riera, E, Bejerano, C, Castañeda, S, Blanco, R. Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review. RMD Open. 2026; 12(1)DOI:10.1136/rmdopen-2025-006549. PMID:41856562. IF:4.700(Q1/1D).

01/03/2026 B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment

Agmon-Levin, N, Ignatenko, S, Gordienko, A, Cortés-Hernández, J, Narongroeknawin, P, Romanowska-Próchnicka, K, Shen, N, Ciferska, H, Kodera, M, Cheng-Chung, WJ, Leszczynski, P, Lan, JL, Mysler, E, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Lie, D, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, López, BPM, Ghanshani, SA, Lau, C, Avrameas, A, Sips, C, Oliver, SJ. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(3)DOI:10.1016/j.ard.2025.11.015. PMID:41353079. IF:20.600(Q1/1D).

01/04/2026 The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

Petelytska, L, Tofani, L, Velauthapillai, A, Dobrota, R, Becker, MO, Mihai, C, Muraru, S, Elhai, M, Jordan, S, Hachulla, E, Müller-Ladner, U, Siegert, E, Allanore, Y, Riemekasten, G, Bergmann, C, Becvar, R, Solanki, K, Anic, B, Szabo, I, Stamenkovic, B, Distler, J, Carreira, PE, Cuomo, G, Castellví, I, Balbir-Gurman, A, Airo, P, Litinsky, I, Saketkoo, LA, Bertaccini, B, Vonk, M, de Vries-Bouwstra, J, Hoffmann-Vold, AM, Matucci-Cerinic, M, Distler, O, Bruni, C. The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133). ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(4)DOI:10.1016/j.ard.2025.12.008. PMID:41549016. IF:20.600(Q1/1D).

01/03/2026 Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients

Loricera, J, Molina-Collada, J, Nieto, JC, Sánchez-Lucas, M, Silva-Díaz, MT, Moya, P, Labrador, E, Ferraz-Amaro, I, Blanco, R. Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients. DRUGS & AGING. 2026; 43(3)DOI:10.1007/s40266-026-01281-1. PMID:41714460. IF:3.800(Q2/3D).

01/04/2026 Rheumatologists' perceptions of biosimilar use in Spain: the CUSTODIAN study

Corominas, H, Guigini, MA, Ameruso, YS, Reina, D. Rheumatologists' perceptions of biosimilar use in Spain: the CUSTODIAN study. CURRENT MEDICAL RESEARCH AND OPINION. 2026; 42(2)DOI:10.1080/03007995.2026.2656544. PMID:42030169. IF:2.200(Q2/3D).

01/06/2024 Allergy to Theobroma Cacao

Valencia, AN, Retes, LS, Bartolomé-Zavala, B, Gutiérrez, GP, Bigorra, T. Allergy to Theobroma Cacao. Clinical Case Reports. 2024; 12(6)DOI:10.1002/ccr3.8803. PMID:38883222. IF:(Q/D).

05/01/2024 Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

del Pozo, V, Bobolea, I, Rial, MJ, Espigol-Frigolé, G, Laqué, RS, Hernández-Rivas, JM, Mora, E, Crespo-Lessmann, A, Alonso, JLI, Sosa, MSD, Maza-Solano, J, Atienza-Mateo, B, Bañas-Conejero, D, Moure, AL, Rúa-Figueroa, I. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases. Frontiers in Immunology. 2024; 14DOI:10.3389/fimmu.2023.1310211. PMID:38250075. IF:5.900(Q1/2D).

01/02/2024 Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function

Quesada-López, T, Cereijo, R, Blasco-Roset, A, Mestres-Arenas, A, Prieto, P, Domingo, JC, Villarroya, F, Domingo, P, Giralt, M. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. BIOCHEMICAL PHARMACOLOGY. 2024; 220DOI:10.1016/j.bcp.2023.116010. PMID:38154544. IF:5.600(Q1/1D).

01/08/2024 BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Provencio, M, de Lope, LR, Serna-Blasco, R, Nadal, E, Tain, PD, Massuti, B, González-Larriba, JL, Insa, A, Sánchez-Hernández, A, Casal-Rubio, J, Garcia-Campelo, R, López, SS, Rogado, J, Martínez-Martí, A, Bosch-Barrera, J, Bernabé, R, Estévez, SV, Ponce, S, de Castro, J, Sarto, JC, Reguart, N, Dómine, M, Aguilar, A, Majem, M, Estival, A, Cabia, SP, Martín, AL, González, MAS, Cobo, M, Camps, C, Barneto, I, Calvo, V, Collazo-Lorduy, A, Cruz-Bermúdez, A, Romero, A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. LUNG CANCER. 2024; 194DOI:10.1016/j.lungcan.2024.107865. PMID:38945004. IF:4.400(Q1/2D).

01/07/2025 Impact of Alzheimer's disease on sleep in adults with Down syndrome

Giménez, S, Vaqué-Alcázar, L, Zhu, NL, Benejam, B, Arranz, J, Maure-Blesa, L, Videla, L, Carmona-Iragui, M, Barroeta, I, Rebillat, AS, Rodriguez-Baz, I, Bejanin, A, Arriola-Infante, JE, Bueno, A, Fernandez, S, Ribas, L, Zsadanyi, SE, Morcillo-Nieto, AO, Alcolea, D, Lisgaras, CP, Blessing, E, Osorio, RS, Lleo, A, Fortea, J. Impact of Alzheimer's disease on sleep in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(7)DOI:10.1002/alz.70400. PMID:40604343. IF:11.100(Q1/1D).

01/02/2026 Neoadjuvant (neoadj) durvalumab (D) plus chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study

Buchmeier, EL, Reck, M, Girard, N, Nadal, E, Gay, CM, Filippi, AR, Martin, LW, Petersen, C, Cairns, DA, Roch, B, Attili, I, Alvarez, RA, Boyer, A, Tarruella, MM, Robinson, A, Levra, MG, Li, L, Perez, ID, Georgoulia, N, Spicer, J. Neoadjuvant (neoadj) durvalumab (D) plus chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

01/02/2026 International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease

Giani, C, Baldi, GG, Ljevar, S, Denu, RA, Andelkovic, V, Han, I, Brunello, A, Napolitano, A, Bhadri, VA, Scanferla, R, Garcia, AS, Abreu, MH, Campos, F, Ogura, K, Wong, DD, Bae, S, Marquina, G, Mazzocca, A, Yang, V, Nakazawa, MS, Kim, HS, Chiusole, B, Thway, K, Antonescu, C, Bellan, E, Bovée, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Chen, TWW, Miceli, R, Gronchi, A, Stacchiotti, S. International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease. ESMO Open. 2026; 11(2)DOI:10.1016/j.esmoop.2025.106044. PMID:41564817. IF:8.300(Q1/2D).

01/02/2026 IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC

Christoph, D, Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, R, Stencel, K, Tarruella, MM, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Cuchelkar, V, Graupner, V, Kaul, M, Lin, YC, Chakrabarti, D, Bhatt, K, Reck, M. IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

01/01/2026 Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)

López-Tarruella, S, Guerrero-Zotano, A, Antolín, S, Cruz, J, Martínez, P, Rodríguez, CA, Falo, C, Rodríguez-Lescure, A, Adrover, E, Hernández, M, Andrés, R, Chacón, JI, Romero, JLA, Miguel, A, Gómez-Raposo, C, Margelí, M, González, I, Guerra, JA, Antón, A, Tibau, A, Miralles, JJ, Escudero, MJ, Bezares, S, Rojo, F, Alvarez, I. Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). Therapeutic Advances in Medical Oncology. 2026; 18DOI:10.1177/17588359261421813. PMID:41732657. IF:4.200(Q2/3D).

01/01/2026 Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

Capdevila, J, Paez, D, Villacampa, MM, Garcia-Alvarez, A, Aparicio, J, Pampols, M, Riesco-Martinez, MD, Polo, E, Ruiz-Casado, A, Castañon, C, Soriano, S, Hernando, J, Navalpotro, B, Armario, D, Villacampa, G, Horvath, E, Virgili, AC, Asiain, L, Giménez, A, Guillot, M. Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.11. PMID:. IF:41.900(Q1/1D).

01/01/2026 A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.

Hayes, M, Nakajima, TE, Seecof, O, Majem, M, Chenji, S, Ashki, N, Ceccarelli, M, Van Cutsem, E. A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.TPS855. PMID:. IF:41.900(Q1/1D).

01/01/2026 Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry

Martín, AJM, Castet, F, Vera, R, Alvarez, R, Garcia-Alfonso, P, Alsar, JS, Palao, P, Diaz, IA, Vidal-Tocino, R, Adeva, J, Modrego, A, Maseda, AC, Martínez-Galán, J, Serda, PC, Rodriguez-Alonso, RM, Aranda, E, La Casta, A, de Castro, EM, Montes, AFF, Macarulla, T. Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.500. PMID:. IF:41.900(Q1/1D).

01/01/2026 ERBB2/HER2 status in biliary tract cancer patients in the Spanish RETUD registry.

Martín, AJM, Castet, F, Vera, R, Alvarez, R, Pertusa, C, Garcia-Alfonso, P, Rodríguez, RJ, Vidal-Tocino, R, Diaz, IA, Caro, NL, Adeva, J, Paladines, WGP, Maseda, AC, Rodriguez-Alonso, RM, Aranda, E, Serda, PC, de Castro, EM, La Casta, A, Laquente, B, Macarulla, T. ERBB2/HER2 status in biliary tract cancer patients in the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.498. PMID:. IF:41.900(Q1/1D).

01/05/2025 Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies

Alonso-Gordoa, T, Anguera, G, Domínguez-Esteban, M, Reig, O, Martínez-Barros, H, Molina-Cerrillo, J, Cruz, P, Maroto, P. Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. CANCER TREATMENT REVIEWS. 2025; 136DOI:10.1016/j.ctrv.2025.102925. PMID:40186886. IF:10.500(Q1/1D).

14/02/2024 Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

Favaro, MTP, Alamo, P, Roher, N, Chillon, M, Lascorz, J, Márquez, M, Corchero, JL, Mendoza, R, Martínez-Torró, C, Ferrer-Miralles, N, Ferreira, LCS, Mangues, R, Vázquez, E, Parladé, E, Villaverde, A. Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses. ACS Materials Letters. 2024; 6(3)DOI:10.1021/acsmaterialslett.3c01643. PMID:. IF:8.700(Q1/2D).

01/05/2026 European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage

Vergouwen, MDI, Ramos-Pachon, A, Terecoasa, EO, Willett, N, Cuadrado-Godia, E, Gaberel, T, Gizewski, ER, Helbok, R, Ho, LA, Hugelshofer, M, Korja, M, Meling, TR, Psychogios, MN, Rinkel, GJE, Taschner, CA, Vajkoczy, P, Etminan, N. European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage. European Stroke Journal. 2026; 11(5)DOI:10.1093/esj/aakag043. PMID:42095754. IF:4.500(Q1/2D).

01/04/2026 Early care limitation after ICH in a population-based study: what drives clinicians' decisions?

Lambea-Gil, A, Camps-Renom, P, Martí-Fàbregas, J, Guasch-Jiménez, M, Ezcurra-Díaz, G, Fernández-Vidal, JM, Prats-Sanchez, L, Martínez-Domeño, A, de la Ossa, NP, Ramos-Pachón, A. Early care limitation after ICH in a population-based study: what drives clinicians' decisions?. European Stroke Journal. 2026; 11(4)DOI:10.1093/esj/aakag028. PMID:41947561. IF:4.500(Q1/2D).

01/12/2024 Nemaline Myopathy Type 6 Caused by Variants in the KBTBD13 Gene

van Kleef, ESB, Bouman, K, Molenaar, JPF, Küsters, B, Groothuis, JT, Olivé, M, Malfatti, E, Kamsteeg, EJ, Van Engelen, BGM, Ottenheijm, CAC, Doorduin, J, Voermans, NC. Nemaline Myopathy Type 6 Caused by Variants in the KBTBD13 Gene. Neurology-Genetics. 2024; 10(6)DOI:10.1212/NXG.0000000000200214. PMID:39651462. IF:3.700(Q1/3D).

01/03/2026 Recommendations for the diagnostic, treatment, and follow-up of late-onset Pompe disease

Dominguez-González, C, Romero, MAB, Eraso, CC, de las Heras, J, Muñoz, EF, Garcia-Campos, O, González, M, Grau, JM, Hernández-Voth, A, Morales, RJ, Hernández, JCL, Martos, ML, López-Padilla, D, Muelas, N, Nascimento, A, Olivé, M, Paradas, C, Fernández, JP, Pascual, SI, Pitarch, I, Sancho, J, Diaz-Manera, J. Recommendations for the diagnostic, treatment, and follow-up of late-onset Pompe disease. NEUROLOGIA. 2026; 41(2)DOI:10.1016/j.nrl.2025.501933. PMID:41453611. IF:3.100(Q2/4D).

01/01/2026 Muscle Imaging in Inclusion Body Myositis: Refinement of MRI Criteria and Insights Into Upper Body Involvement

Torchia, E, Lucchini, M, Verdu-Diaz, J, Bortolani, S, Ravera, B, Carlomagno, V, Cicia, A, Bernardo, D, Monforte, M, Rehmann, R, Kley, RA, Sabatelli, M, Díaz-Manera, J, Ricci, E, Mirabella, M, Tasca, G. Muscle Imaging in Inclusion Body Myositis: Refinement of MRI Criteria and Insights Into Upper Body Involvement. Journal of Cachexia Sarcopenia and Muscle. 2026; 17(1)DOI:10.1002/jcsm.70173. PMID:41549703. IF:9.100(Q1/1D).

01/03/2026 Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial

Doneddu, PE, Collet-Vidiella, R, Gallo, C, Cocito, D, Manganelli, F, Falzone, Y, Dalla Bella, E, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2026; 31(1)DOI:10.1111/jns.70107. PMID:41649095. IF:3.200(Q2/4D).

01/03/2026 Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain

De Pedro, S, Presa, M, Gamez, J, Fernández, FJG, Querol, L. Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain. Pharmacoeconomics-Open. 2026; 10(2)DOI:10.1007/s41669-025-00633-8. PMID:41528376. IF:(Q/D).

01/05/2024 Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis

Costas-Carrera, A, Verdolini, N, Garcia-Rizo, C, Mezquida, G, Janssen, J, Valli, I, Corripio, I, Sanchez-Torres, AM, Bioque, M, Lobo, A, Gonzalez-Pinto, A, Rapado-Castro, M, Vieta, E, de la Serna, H, Mane, A, Roldan, A, Crossley, N, Penades, R, Cuesta, MJ, Parellada, M, Bernardo, M. Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis. PSYCHOLOGICAL MEDICINE. 2024; DOI:10.1017/S0033291723003185. PMID:38014924. IF:5.500(Q1/1D).

01/02/2024 Correction: Electroconvulsive therapy-induced volumetric brain changes converge on a common causal circuit in depression.

Argyelan M, Deng ZD, Ousdal OT, Oltedal L, Angulo B, Baradits M, Spitzberg AJ, Kessler U, Sartorius A, Dols A, Narr KL, Espinoza R, van Waarde JA, Tendolkar I, van Eijndhoven P, van Wingen GA, Takamiya A, Kishimoto T, Jorgensen MB, Jorgensen A, Paulson OB, Yrondi A, Péran P, Soriano-Mas C, Cardoner N, Cano M, van Diermen L, Schrijvers D, Belge JB, Emsell L, Bouckaert F, Vandenbulcke M, Kiebs M, Hurlemann R, Mulders PC, Redlich R, Dannlowski U, Kavakbasi E, Kritzer MD, Ellard KK, Camprodon JA, Petrides G, Malhotra AK, Abbott CC. Correction: Electroconvulsive therapy-induced volumetric brain changes converge on a common causal circuit in depression.. MOLECULAR PSYCHIATRY. 2024; 29(2)DOI:10.1038/s41380-023-02358-8. PMID:38052984. IF:(Q/D).

01/01/2024 Patterns of Use and Withdrawal Syndrome in Dual Cannabis andTobacco Users (DuCATA_GAM-CAT):Protocol for a MixedMethods Study

Saura, J, Feliu, A, Enriquez-Mestre, M, Fu, M, Ballbe, M, Castellano, Y, Pla, M, Rosa, N, Radeva, P, Maestre-Gonzalez, E, Cabezas, C, Colom, J, Suelves, JM, Mondon, S, Barrio, P, Andreu, M, Raich, A, Bernabeu, J, Vilaplana, J, Tutusaus, XR, Guydish, J, Fernandez, E, Martinez, C. Patterns of Use and Withdrawal Syndrome in Dual Cannabis andTobacco Users (DuCATA_GAM-CAT):Protocol for a MixedMethods Study. Jmir Research Protocols. 2024; 13DOI:10.2196/58335. PMID:39298750. IF:(Q/D).

01/09/2021 AMYQ: An index to standardize quantitative amyloid load across PET tracers

Pegueroles, J, Montal, V, Bejanin, A, Vilaplana, E, Aranha, M, Santos-Santos, MA, Alcolea, D, Carrio, I, Camacho, V, Blesa, R, Lleo, A, Fortea, J. AMYQ: An index to standardize quantitative amyloid load across PET tracers. ALZHEIMERS & DEMENTIA. 2021; 17(9)DOI:10.1002/alz.12317. PMID:33797846. IF:16.655(Q1/1D).

01/10/2024 Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain)

Abras, A, Ballart, C, Fernández-Arévalo, A, Llovet, T, Gállego, M, Muñoz, C. Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain). Life-Basel. 2024; 14(10)DOI:10.3390/life14101278. PMID:39459578. IF:3.400(Q1/3D).

04/05/2024 Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

Salamanca-Rivera, E, Palacios-Baena, ZR, Cañada, JE, Moure, Z, Pérez-Vázquez, M, Calvo-Montes, J, Martínez-Martínez, L, Cantón, R, Carrascoso, GR, Pitart, C, Navarro, F, Bou, G, Mulet, X, González-López, JJ, Sivianes, F, Delgado-Valverde, M, Pascual, A, Oteo-Iglesias, J, Rodríguez-Baño, J. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain. INFECTION. 2024; DOI:10.1007/s15010-024-02267-0. PMID:38703288. IF:3.600(Q2/3D).

03/06/2024 A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1

Agarwal, N, Castellano, D, Alonso-Gordoa, T, Arija, JAA, Colomba, E, Gravis, G, Mourey, L, Oudard, S, Fléchon, A, González, M, Rey, PM, Schweizer, MT, Gallardo, E, Johnston, E, Balar, A, Haddad, N, Appiah, AK, Nacerddine, K, Piulats, JM. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1. CLINICAL CANCER RESEARCH. 2024; 30(11)DOI:10.1158/1078-0432.CCR-23-3436. PMID:38512117. IF:10.200(Q1/1D).